FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma —Are We Hitting the Target?
ConclusiontTAD of ≥ 200 cGy may prove valuable to ensure clinical response, but further studies are needed to confirm this in a larger patient population. Furthermore, this work indicates that higher baseline tumor burden (up to 585 cm3) did not induce reduction in radioimmunoconjugate accumulation in tumor.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
More News: Biology | CT Scan | Hodgkin's Disease | Lymphoma | Molecular Biology | Non-Hodgkin's Lymphoma | PET Scan | SPECT | Study